125: On the Physical and Dosimetric Properties of 3D Printed Electron Bolus Fabricated Using Polylactic Acid  by McCowan, Peter et al.
CARO 2016                                                                                                                                                                  S47 
_________________________________________________________________________________________________________ 
were blinded to clinical outcomes. Radiomic features (first-
order, second-order grey-level co-occurrence matrix, and size- 
and shape-based) were extracted from the same images. 
Performance of the physician assessors and the radiomics 
signatures were compared.  
Results: A total of 182 follow up CT scans were analyzed with a 
median imaging follow up of 20 months. When taking into 
account all CT scans during the entire follow up period, median 
sensitivity for physician assessment of local recurrence was 83% 
(range 67–100%) and specificity was 75% (range 67–87%), with 
only moderate inter-observer agreement (kappa=0.54). The 
median time to detection of recurrence across all observers was 
15.5 months. When predicting recurrence using images acquired 
< 6 months post-SABR, physicians assessed the majority of images 
as benign injury/no recurrence, with a mean error of 35%, false 
positive rate (FPR) of 1%, and false negative rate (FNR) of 99%. 
At the same time point, a radiomic signature consisting of five 
post-SABR image appearance features in the consolidative and 
surrounding peri-consolidative regions demonstrated excellent 
discrimination, with an area under the receiver operating 
characteristic curve of 0.85, leave-one-out cross-validation 
classification error of 24%, FPR of 24%, and FNR of 23%.  
Conclusions: These results suggest that radiomics can detect 
early changes associated with local recurrence that are not 
typically considered by physicians. Patients with recurrence tend 
to have increased presence of ground-glass opacity surrounding 
consolidative changes compared to patients with benign injury 
at this early follow up time point. These appearances detected 
by radiomics may be early indicators of the promotion and 
progression to local recurrence; our ongoing studies include using 
correlative histology to determine their composition. This has 
the potential to lead to a clinically useful computer aided 
decision support tool based on routinely acquired CT imaging, 
which could lead to earlier life-saving salvage opportunities for 
patients with local recurrence following SABR. 
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Purpose: A fused deposition modeling three dimensional printer 
is currently being commissioned at our centre for fabrication of 
electron bolus. The main advantage in using a 3D printer for this 
purpose is that virtually any shape can be produced, potentially 
providing a more accurate way to compensate for irregular 
surfaces that can change the dose distribution within the 
patient. PLA is one of the most commonly used 3D printer 
materials. Compared to ABS, PLA is less likely to warp due to 
heating and cooling during printing. For less expensive printers 
which may not have heated printing beds or thermally controlled 
environments, it is especially appealing. Before PLA boluses can 
be clinically used, their physical and dosimetric properties must 
be characterized. The purpose of this study was to characterize 
the density, dimensional accuracy, uniformity, and attenuation 
of PLA boluses fabricated with our printer. 
Methods and Materials: Several uniform solid square slabs were 
printed with specific requested dimensions and 100% infill using 
concentric and rectilinear fill patterns. These pieces were 
imaged using an x-ray flat panel imager in order to check for 
uniformity of the print. The PLA slabs were placed on solid water 
and irradiated with a 12 MeV electron beam. Percentage depth 
doses (PDDs) were measured downstream of the slabs using a 
parallel plate chamber and compared to measurements in water. 
The dimensions of the PLA slabs were measured using digital 
calipers in several locations, and the average was compared to 
design values. The slabs were also weighed using a digital scale 
to find their average density relative to water. 
Results: X-ray imaging showed that certain fill patterns can 
create local errors in density where the printer’s extruder 
changes direction. This can produce significant changes in dose - 
in one case there was a > 10% surface dose directly under the 
defect. Fill patterns which eliminate changes in extruder 
direction in sensitive regions (e.g. a rectilinear pattern) 
eliminated such defects. PLA causes the electron PDD to shift 
towards shallower depths, compared to water, by 1.7 mm for 
each centimeter of PLA due to its increased density. This can be 
taken into account during treatment planning, provided the 
thickness of PLA is roughly constant over the area to be treated. 
This may not be the case if treating very large regions with 
complex contours. Agreement with design dimensions was within 
1 mm in the plane of the printer bed, and within 1/3 of a 
millimeter (roughly the thickness of a single layer), 
perpendicular to the printer bed. Average density relative to 
water was in the range 1.20 – 1.22. 
Conclusions: 3D printing shows great promise for use in 
fabricating electron bolus. This work indicates that PLA can be a 
suitable material provided the increased attenuation is properly 
accounted for. 
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Purpose: To develop and test a radiochromic-based in-vivo skin 
dosimetry protocol for permanent breast 103Pd seed implant 
brachytherapy (PBSI) and to compare measured doses with the 
calculated by a commercial TG43-based treatment planning 
system.  
Methods and Materials: EBT3 radiochromic films were calibrated 
using an ad-hoc acrylic phantom and 103Pd seeds. EBT3 films 
strips from the calibrated EBT3 batch and measuring 
approximately 2x15 cm2 were positioned directly over the breast 
skin of 13 patients implanted with103Pd seeds. The EBT3 
filmstrips were positioned immediately after the PBSI procedure 
and were centred on the skin projection of the patient’s seroma 
and were fixed to the breast skin of the patients using 
TransporeTM film. No gauze or any other material was placed on 
top of the EBT3 filmstrip. However, a TagadermTM transparent 
film dressing was placed over the area of the implant to prevent 
direct contact of the EBT3 filmstrip with the patient’s skin. The 
average exposure time for the films was four hours. The films 
were evaluated at least 24 hours after exposure following an in 
house EBT3 radiochromic evaluation protocol. The maximum 
actual measured dose defined as the 10x10 mm2 region that 
exhibited the maximum net optical density on the filmstrip was 
used to estimate the dose to the breast skin by integration over 
the life of the 103Pd seeds. The maximum dose to the skin at the 
filmstrip position was also calculated using the TG43-based MIM 
MAESTROTM treatment planning system (TPS). A structure 
extending 0.5 mm from the body was constructed to mimic the 
filmstrip, at position at a similar location with respect to the 
seroma. The dose within the filmstrip was obtained as the 
maximum dose to a volume of 10x10x0.5 mm3 (0.05 cm3).  
Results: In general the dose calculations underestimated the 
EBT3-based measurements. For the highest dose measured (81.3 
± 4.9 and 82.3 ± 3.0 Gy) the corresponding calculated doses were 
slightly lower (7% on average). For the intermediate dose range 
(40 to 60 Gy, seven patients) the dose calculations were 
approximately 50% lower than the measured doses. For the 
lowest doses measured (20-40 Gy, four patients), the calculated 
dose were on average 15% lower than the measured. The good 
agreement at high and low doses is unexpected given the 
expected dose overestimation of the TG43-based TPS. The large 
